替吉奥联合TP化疗方案对中晚期宫颈癌患者免疫功能及肿瘤标志物的影响OA

Objective:To explore the effect of a combined regimen(Tegio+TP chemotherapy)on patients with advanced cervical cancer.Methods:Sixty patients with advanced cervical cancer admitted to our hospital from August 2021 to August 2023 were selected and divided into two groups based on different treatment methods,with 30 cases in each group.The control group was given a TP chemotherapy regimen,while the observation group was given a combination regimen(tigio+TP chemotherapy).Compare the recent clinical efficacy and toxic side effects between two groups,and compare the changes in inflammatory fac-tors,immune function,and tumor markers before and after treatment.Results:After treatment,there was no statistically sig-nificant difference in the proportion of ORR between the two groups(P>0.05),but the proportion of DCR in the observation group was 86.67%higher than that in the control group,which was 60.00%(P<0.05);After treatment,the observation group TNF-α、TGF-βThe levels were all lower than the control group,and the observation group had higher levels of CD3+,CD4+,CD4+/CD8+than the control group.The levels of CD8+,CAl25,CEA,and SCCA were all lower than the control group(all P<0.05);There was no statistically significant difference in the incidence of toxic side effects between the two groups(P>0.05).Conclusion:The combination of Tegio and TP chemotherapy in patients with advanced cervical cancer can effectively improve disease control rate,improve immune function and tumor markers,inhibit inflammatory response,and not easily increase toxic side effects.It is worth clinical reference and application.